
A drop-off of 20 %.
That was the reaction from the stock market to Zealand Pharma’s share following an announcement revealing that the combination product involving the Danish biotech company’s invention Lyxumia and insulin-product Lantus from French pharma group Sanofi is delayed and will not be entering phase III studies in 2013 as expected.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app